Back to News
Market Impact: 0.25
Trump Administration Working on More Drug Pricing Deals, Oz Says
Source: Bloomberg
Healthcare & BiotechRegulation & Legislation
CMS Administrator Mehmet Oz said the Trump administration is pursuing additional drug-pricing deals with pharmaceutical companies. No companies, pricing terms, expected savings, or implementation timeline were disclosed, limiting the immediate read-through for individual drugmakers.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- How This County Made the Data Center Boom Pay Off